Week In Review: Mundipharma Considers $1 Billion Sale Of China Operations

Mundipharma is considering selling its China operations in a deal that could be worth $1 billion. Additionally, Oramed Pharma plans to form a $60 million JV with Hefei Tianhui Biotech to commercialize Oramed's oral drug delivery products globally.